The interaction between prognostic and pharmacodynamic biomarkers

Background:Interactions between prognostic and pharmacodynamic (PD) biomarkers have received little attention.Methods:Prognostic and PD utilities were assessed with linear mixed-effects models using published data on repeated measurements of circulating caspase-cleaved (ctCK18) and total (tCK18) cytokeratin 18, in 57 patients with metastatic colorectal cancer undergoing chemotherapy.Results:The model for tCK18 (but not cCK18) separated the prognostic/PD interaction from the pure prognostic effect, illustrating the principle of dual prognostic and PD characteristics for a given biomarker.Conclusion:These models provide the framework for the analysis and interpretation of longitudinal data to detect prognostic/PD biomarker interactions.

• Publication year

  2013

• Venue

  British Journal of Cancer

• Publication date

  2013-09-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bjc.2013.527PMID 24002599PMCID 3790178
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer

  2012cited by this paper
• Analysis of Longitudinal and Survival Data: Joint Modeling, Inference Methods, and Issues

  2012cited by this paper
• Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma

  2011cited by this paper
• Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

  2011cited by this paper
• Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

  2010cited by this paper
• Biomarkers and surrogate end points—the challenge of statistical validation

  2010cited by this paper
• Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo

  2010cited by this paper
• Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

  2010cited by this paper
• Basic concepts and methods for joint models of longitudinal and survival data.

  2010cited by this paper
• Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

  2009cited by this paper
• Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development

  2009cited by this paper
• Longitudinal Data Analysis. Handbooks of Modern Statistical Methods

  2009influential reference
• Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

  2008cited by this paper
• Clinical Relevance of Circulating Nucleosomes in Cancer

  2008cited by this paper
• Optimisation of circulating biomarkers of cell death for routine clinical use.

  2008cited by this paper
• Pharmacodynamic biomarkers for molecular cancer therapeutics.

  2007cited by this paper
• Modeling Longitudinal Data

  2006cited by this paper
• Circulating fragmented nucleosomal DNA and caspase-3 mRNA in patients with lymphoma and myeloma.

  2006cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000influential reference
• New guidelines to evaluate the response to treatment in solid tumors

  2000influential reference
• Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected].

  1993cited by this paper
• Sample size requirements and length of study for testing interaction in a 1 × k factorial design when time-to-failure is the outcome

  1993cited by this paper

• No citing papers are available for this paper.